[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 4, 2000

The Role of Genotypic Resistance Testing in Selecting Therapy for HIV

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(13):1649-1650. doi:10.1001/jama.284.13.1647

To the Editor: The usefulness of genotype resistance testing in the clinical management of HIV infection is increasingly clear. However, as Dr Hirsch and colleagues1 state, several technical issues concerning standardization and clinical validation have yet to be resolved.

Although genotypic assays are increasingly common in the clinical setting, interpretation of results is more complex than merely identifying mutations and then eliminating antiretroviral drugs that supposedly are not efficacious. In fact, the same combinations of primary and secondary mutations may result from several different scenarios.

First Page Preview View Large
First page PDF preview
First page PDF preview
×